Please login to the form below

Not currently logged in
Email:
Password:

Teva sues Apotex to block generic Coreg

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Apotex, Teva and other generic-drug makers won FDA approval to sell the generic version on 5 September 2007. Teva says that it owns four patents which cover various forms and processes to make carvedilol.

To sell carvedilol, says Teva, Apotex might have to purchase the compound made using the patented process. Apotex has not supplied the necessary data required to rule whether the generic uses patented processes or not. Teva has filed for a court order to prevent patent infringement by Apotex.

For H1 FY07, Coreg posted sales of USD 854m and analysts say that the annual generic market for carvedilol could be worth as much as USD 50m.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics